|
BCCIP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.5527136788005E-15 |
| Normal-vs-Stage2 |
1.02669999946237E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.885400E-01 |
| Stage1-vs-Stage3 |
1.311630E-02 |
| Stage1-vs-Stage4 |
2.71050000000272E-06 |
| Stage2-vs-Stage3 |
8.877000E-03 |
| Stage2-vs-Stage4 |
9.83650000000447E-05 |
| Stage3-vs-Stage4 |
1.101390E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.5227000044481E-08 |
| Normal-vs-Asian |
1.88848936488739E-12 |
| Caucasian-vs-AfricanAmerican |
8.520600E-01 |
| Caucasian-vs-Asian |
8.480400E-01 |
| AfricanAmerican-vs-Asian |
9.371800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
3.228600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66922031752392E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.69353420176321E-12 |
| Normal-vs-Age(81-100Yrs) |
1.848430E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.893590E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.243800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.838000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.213000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.371400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.195000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.447400E-04 |
| Classical-VS-Follicular |
1.160230E-03 |
| Classical-VS-Other |
9.770200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.14120000005435E-07 |
| Tall-VS-Other |
2.568600E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
3.125800E-01 |
| Follicular-VS-Normal |
1.23530000006866E-07 |
| Other-VS-Normal |
2.649300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.16573417585641E-14 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.243500E-04 |
|
|
